Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs YieldMax AMD Option Income Strategy ETF (AMDY) Price & Performance

AbbVie IncTrade
YieldMax AMD Option Income Strategy ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs YieldMax AMD Option Income Strategy ETF — how do they compare? AbbVie Inc trades at $248.76 (market cap $441.94B), while YieldMax AMD Option Income Strategy ETF trades at $45.66. The key difference: AbbVie Inc pays a 2.77% dividend while YieldMax AMD Option Income Strategy ETF pays none, and AbbVie Inc is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

ABBVAMDY
Market Cap
$441.94B
Sector
HealthIncome / Options Overlay
52-Week High
$263.58$59.52
52-Week Low
$197.38$29.80
Enterprise Value
$506.19B
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.

Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.

YieldMax AMD Option Income Strategy ETF

AMDY trades at $45.66, up 2.47% with a bearish technical signal from moving averages. The ETF generates high weekly distributions but faces concerns about NAV erosion during AMD volatility. Recent Seeking Alpha analysis rates it HOLD, noting the strategy works best when AMD rises gradually rather than accelerating sharply.

Outlook remains cautious due to structural NAV erosion risks. The high-yield strategy provides income opportunity but requires careful timing. Key risks include AMD's performance volatility and the ETF's call spread strategy limitations during market downturns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About YieldMax AMD Option Income Strategy ETF

AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.

Read more on AMDY